Serum Sortilin Levels as a Biomarker for Metabolic and Hormonal Dysregulation in Polycystic Ovary Syndrome
Journal of Personalized Medicine · 15.02.2025 · 15 (2) · 70
DOI: 10.3390/jpm15020070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 15.02.2025. Verfasst von Pinar Alarslan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine and Metabolic Diseases, Istanbul Aydin University, Medical Park Florya Hospital, Besyol, Florya, Akasya Sk., 34295 Kucukcekme…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Polycystic ovarian syndrome (PCOS) is a complex endocrine disorder affecting up to 15% of reproductive-age women, characterized by hyperandrogenism, chronic oligo-ovulation, and metabolic dysfunction. This study aims to evaluate serum sortilin levels in women with PCOS for the first time and investigate their potential associations with metabolic and hormonal alterations. Material and Methods: Eighty PCOS patients and 80 healthy controls were included; serum sortilin levels were measured using ELISA kits, with documented intra-assay and inter-assay variations below 6% and 8%, respectively, ensuring high specificity and sensitivity.
Results
Serum sortilin levels were significantly elevated in PCOS patients (69.51 ± 27.75 pg/mL) versus controls (48.60 ± 21.20 pg/mL) (p < 0.001). PCOS patients exhibited higher mean HOMA-IR, free androgen index values, serum glucose, insulin, triglycerides, high-sensitivity C-reactive protein, luteinizing hormone, total testosterone, and DHEA-S levels, alongside reduced high-density lipoprotein cholesterol and sex hormone-binding globulin levels (all, p < 0.05). Notably, inverse correlations were observed between sortilin and low-density lipoprotein cholesterol levels in both groups (p = 0.028 and 0.033).
Conclusions
This pioneering study indicates that serum sortilin may be implicated in PCOS pathogenesis and serves as a potential biomarker for metabolic dysfunction in PCOS. Larger, diverse studies with longitudinal designs are needed for further validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrine and Metabolic Diseases, Istanbul Aydin University, Medical Park Florya Hospital, Besyol, Florya, Akasya Sk., 34295 Kucukcekmece/Istanbul, Turkey.
- Department of Endocrine and Metabolic Diseases, İzmir Bozkaya Research and Education Hospital, Bahar, Saim Çıkrıkçı Cd., 35170 Karabağlar/İzmir, Turkey.
Zitieren
APA
Alarslan, P., & Doruk, M. (2025). Serum Sortilin Levels as a Biomarker for Metabolic and Hormonal Dysregulation in Polycystic Ovary Syndrome. Journal of Personalized Medicine, 15(2), 70. https://doi.org/10.3390/jpm15020070
Vancouver
Alarslan P, Doruk M. Serum Sortilin Levels as a Biomarker for Metabolic and Hormonal Dysregulation in Polycystic Ovary Syndrome. Journal of Personalized Medicine. 2025;15(2):70. doi:10.3390/jpm15020070
BibTeX
@article{Alarslan2025,
author = {Alarslan, Pinar and Doruk, Mehmet},
title = {Serum Sortilin Levels as a Biomarker for Metabolic and Hormonal Dysregulation in Polycystic Ovary Syndrome},
journal = {Journal of Personalized Medicine},
year = {2025},
volume = {15},
number = {2},
pages = {70},
doi = {10.3390/jpm15020070}
}
EUVIMED